The Mechanism of Leptin Resistance in Obesity and Therapeutic Perspective.
Level 5 - mechanism / opinion, no new human data
Narrative review summarizing mechanisms and therapeutics without systematic methodology or original human data
PubMed 39287862 · doi:10.1007/978-3-031-63657-8_16
What was done
This narrative review synthesized physiological and molecular mechanisms contributing to leptin resistance in obesity—focusing on blood-brain barrier transport limitations and intracellular hypothalamic signaling defects—and surveyed potential pharmacological and surgical interventions.
What was found
The abstract reports no quantitative data or effect sizes. It describes central leptin resistance as driven by impaired leptin transport across the blood-brain barrier (worsened by hypertriglyceridemia) rather than intrinsic hypothalamic leptin insensitivity, alongside signaling blocks via SOCS-3 upregulation and reduced pSTAT3 signaling. Pharmacological agents (such as metformin, anagliptin, miglitol, exendin-4, and tubastatin) and bariatric or contouring surgeries are noted to modulate leptin concentrations or sensitivity, but no clinically effective application for reversing leptin resistance currently exists.
Why it matters
It highlights that leptin resistance is primarily constrained by blood-brain barrier transport dynamics and complex metabolic circuit integration, clarifying why simple leptin replacement or targeting strategies have largely failed clinically.
Limits
As a narrative review, it presents no original empirical data or systematic review methodology. The abstract provides no quantitative metrics, sample sizes, or formal risk of bias assessments for the cited primary studies.
Cited by
- contradicts Leptin resistance is caused by the chronic consumption of refined carbohydrates and starches.